Who
Walid Abi-Saab
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, uniQure.
In numbers
- Trades disclosed
- 33
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $5.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Mar 2024
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $56K10,000 at $5.59 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $465K10,000 at $46.46 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $928K20,000 at $46.40 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $56K10,000 at $5.59 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $465K10,000 at $46.46 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $928K20,000 at $46.40 | filing |
| 26 Jun 2026filed 30 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $67K1,434 at $46.86 | filing |
| 26 Jun 2026filed 30 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $67K1,434 at $46.86 | filing |
| 8 May 2026filed 12 May 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $140K25,000 at $5.59 | filing |
| 8 May 2026filed 12 May 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $628K25,000 at $25.10 | filing |
| 8 May 2026filed 12 May 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $500K20,000 at $25.00 | filing |
| 8 May 2026filed 12 May 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 8 May 2026filed 12 May 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 8 May 2026filed 12 May 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code M | $140K25,000 at $5.59 | filing |
| 8 May 2026filed 12 May 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $628K25,000 at $25.10 | filing |
| 8 May 2026filed 12 May 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $500K20,000 at $25.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —41,700 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $7,320808 at $9.06 | filing |
News
uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $53.25QURE · dailypolitical.com · 24 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)QURE · tickerreport.com · 13 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastQURE · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Walid Abi-Saab; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.